43rd week of 2015 patent applcation highlights part 10 |
Patent application number | Title | Published |
20150297599 | COMPOSITION COMPRISING PHOSPHODIESTERASE TYPE 5 INHIBITOR FOR INHIBITING APOPTOSIS OF NERVE CELLS - The present invention relates to a composition and health functional food for inhibiting apoptosis of cranial nerve cells, and to a method for inhibiting apoptosis, wherein the composition and health functional food comprising a phosphodiesterase type 5 active inhibitor. According to the present invention, the PDE5 inhibitor exhibits a protective effect on nerve cells by inhibiting apoptosis of cranial nerve cells. Thus, the present invention can be effectively used to prevent, alleviate, and treat cranial nerve disease. | 2015-10-22 |
20150297600 | Method Of Achieving Increased Systemic Availability of Methotrexate - Determining that a patient in need of methotrexate requires more systemically available methotrexate than can be obtained by an orally administered dose of methotrexate; and subcutaneously administering a dose of methotrexate to the patient. | 2015-10-22 |
20150297601 | PHOSPHODIESTERASE INHIBITOR TREATMENT - Methods and compositions are disclosed for the treatment of taste and smell disorders. The compositions comprise phosphodiesterase inhibitors and are formulated for intranasal administration. | 2015-10-22 |
20150297602 | DRUGS TO PREVENT HPV INFECTION - A method of inhibiting HPV virus infection is disclosed. In one embodiment, the method involves exposing a papillomavirus to an effective amount of a compound selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14. In another embodiment, the method involves administering an inhibitor selected from the group consisting of Compound 13, Compound 14, and analogs of Compounds 13 and 14 to a susceptible tissue or cell. | 2015-10-22 |
20150297603 | HIGH DRUG LOAD TABLET FORMULATION OF [(1R), 2S]-2-AMINOPROPIONIC ACID 2-[4-(4-FLUORO-2-METHYL-1H-INDOL-5-YLOXY)-5-METHYLPYRROLO[2,1-f][1,2,4]TR- IAZIN-6-YLOXY]-1-METHYLETHYL ESTER - The present invention is directed to a high drug load tablet formulation of [(1R), 2S]-2-aminopropionic acid 2-[4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy]-1-methylethyl ester, and to methods of using the formulation in the treatment of cancer. | 2015-10-22 |
20150297604 | Combination Products with Tyrosine Kinase Inhibitors and their Use - The present invention relates to pharmaceutical products comprising a combination of (i) a MET inhibitor and (ii) an EGFR inhibitor, or a pharmaceutically acceptable salt thereof, respectively, or a prodrug thereof, which are jointly active in the treatment of proliferative diseases, corresponding pharmaceutical formulations, uses, methods, processes commercial packages and related invention embodiments. | 2015-10-22 |
20150297605 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY - Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount a second active agent to a patient having a cancer. | 2015-10-22 |
20150297606 | Tricyclic Lactams for Use in the Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation - This invention is in the area of tricyclic lactam compounds and methods for protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants. | 2015-10-22 |
20150297607 | Tricyclic Lactams for Use in the Protection of Normal Cells During Chemotherapy - This invention is in the area of tricyclic lactam compounds, compositions and methods of protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents. In one aspect, protection of healthy cells is disclosed using compounds that act as cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects undergoing DNA damaging chemotherapeutic regimens for the treatment of proliferative disorders. | 2015-10-22 |
20150297608 | Tricyclic Lactams for Use as Anti-Neoplastic and Anti-Proliferative Agents - This invention is in the area of tricyclic lactam compounds and methods for treating selected cancers and hyperproliferative disorders. | 2015-10-22 |
20150297609 | STERILE OPHTHALMIC PHARMACEUTICAL SUSPENSIONS - An aqueous suspension of a carbonic anhydrase inhibitor such as brinzolamide as well as methods of preparation thereof, are disclosed. The suspension comprises an organic polar solvent such as dimethyl sulfoxide and/or a non-aromatic non-ionic polyethoxylated surfactant such as polyethoxylated castor oil and/or or polysorbate 80. Methods include precipitating brinzolamide from the heated composition. Methods also include sonication of the suspension to reduce brinzolamide particle size. | 2015-10-22 |
20150297610 | METHOD OF WEIGHT MANAGEMENT - Provided are methods of determining if an individual is a responder to treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof. Also provided are methods for selecting an individual for treatment with (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine or a pharmaceutically acceptable salt, solvate or hydrate thereof from a plurality of individuals in need of weight management. Also provided are methods for weight management in an individual in need thereof. Also provided are compounds, compositions, and kits for use in a method of weight management in an individual. | 2015-10-22 |
20150297611 | Inhibition of Histone Methyltransferase for Cardiac Reprogramming - A method for promoting the reprogramming of a non-cardiomyocytic cell or tissue into cardiomyocytic cell or tissue comprising is carried out by contacting a non-cardiomyocytic cell or tissue with a modulator of histone methyltransferase activity or expression. | 2015-10-22 |
20150297612 | METHODS AND COMPOSITIONS FOR TREATING PROGESTERONE-DEPENDENT CONDITIONS - The subject matter of the instant invention is pertinent to the field of treatment of hormone-dependent conditions. Methods for treating these conditions are provided comprising systemically administering an antiprogestin and contemporaneously locally administering an antiprogestin. Embodiments of the instant invention disclose methods for treating endometriosis, dysmenorrhea, breast cancer, uterine fibroids and endometrial hyperproliferation. | 2015-10-22 |
20150297613 | USE OF AGENTS THAT ALTER THE PERITUMORAL ENVIRONMENT FOR THE TREATMENT OF CANCER - The invention relates to the use of agents that alter the peritumoral environment, specifically non-peptide NK1 receptor antagonists, for the treatment of cancer. The peritumoral environment is formed by the stromal cells, the stromal matrix, intra- and peri-tumoral vascularization and the cells responsible for the inflammatory and/or immune response around the tumor. The result of the alteration to the peritumoral environment is a reduction in the size of the tumor, the prevention of its development and, optionally, the induction of its disappearance. The invention also relates to pharmaceutical compositions containing said peritumoral-environment-altering agents, either alone or combined with at least one other active ingredient, for the treatment of cancer. | 2015-10-22 |
20150297614 | COMBINATION OF LEVOCABASTINE AND FLUTICASONE FUROATE FOR THE TREATMENT OF INFLAMMATORY AND/OR ALLERGIC CONDITIONS - The present invention relates to pharmaceutical formulations comprising an anti-inflammatory glucocorticoid compound of the androstane series and levocabastine, an H | 2015-10-22 |
20150297615 | ANDROGEN RECEPTOR INACTIVATION CONTRIBUTES TO ANTITUMOR EFFICACY OF CYP17 INHIBITORS IN PROSTATE CANCER - Provided are methods of inhibiting CYP17 in a mammal, such as a human, that include administering an effective amount of at least one CYP17 inhibitor, such as VN/124-1, VN/125-1, VN/85-1, VN/87-1 and/or VN/108-1 to the mammal. Also provided are methods of down regulating androgen receptor (AR) protein expression and methods of antagonizing AR in a mammal that include administering to the mammal an effective amount of at least one active ingredient selected from VN/124-1, VN/125-1, VN/85-1, VN/87-1 and VN/108-1. Also provided are methods of treating prostate cancer and methods of suppressing or preventing prostate tumor growth by administering such compounds to a mammal. | 2015-10-22 |
20150297616 | A METHOD OF INHIBITING THE EXPRESSION OF IL-22 IN ACTIVATED T-CELLS - The present invention relates to a method of inhibiting the upregulation of the expression of the proinflammatory cytokine interleukin-22 (IL-22) in activated and differentiated human T-cells, said upregulation being induced by administration of a therapeutically effective amount of a phosphodiesterase 4 (PDE4) inhibitor. The method comprises administering, either sequentially to or simultaneously with the administration of the PDE4 inhibitor, a vitamin D receptor agonist in an amount 3) sufficient to inhibit the upregulation of IL-22 expression. | 2015-10-22 |
20150297617 | INTRANASAL MEDICATION DELIVERY DEVICE AND METHOD OF USE THEREOF - The intranasal medication delivery device and method of use thereof includes an elongated malleable member arcuately curved or pre-formed in manner complimentary to the anterior wall of a nasal cavity. One particular embodiment provides the elongated and arcuate member to deliver medication through a lumen such that the medication is deposited in a semi-solid state adjacent the anterior aspect of the nasal cavity lateral wall and to the anterior end of the superior, middle, and inferior turbinate. Another particular embodiment provides the elongated and arcuate member to deliver medication as a suppository to a location similar to that of the previous embodiment. The method of delivering the medicine provides depositing the medicine adjacent the anterior end of one of the superior turbinate, middle turbinate, and inferior turbinate. An exemplary medication can be any one of a corticosteroid, an anti-histamine, an immune active mediator, an IgE binding medication, or a decongestant. | 2015-10-22 |
20150297618 | METHODS OF TREATING ACNE - A method of treating acne in a human in need thereof comprising administering systemically to said human a tetracycline compound in an amount that is effective to treat acne but has substantially no antibiotic activity, without administering a bisphosphonate compound. | 2015-10-22 |
20150297619 | METHODS AND COMPOSITIONS FOR PRESERVING THE MUCOSAL BARRIER - Provided herein are methods and compositions for preventing small molecule permeability of the small intestine curing total ischemia by administering glucose to the lumen of the intestine, as well as administration of serine protease or metalloproteinase inhibitors. Also provided are compositions for performing the same. | 2015-10-22 |
20150297620 | COMPOUNDS FOR USE IN POLYCYSTIC KIDNEY DISEASE - Polycystic kidney disease is a cystic genetic disorder of the kidneys. Recent identification of signaling cascades de-regulated in PKD has led to the initiation of several clinical trials, but an effective therapy is still lacking. A new therapeutic paradigm is capable of improving the proliferation rate and cystic kidney volume in PKD. | 2015-10-22 |
20150297621 | COMPOSITIONS INCLUDING TRICIRIBINE AND TAXANES AND METHODS OF USE THEREOF - This application relates to combination therapies including triciribine and related compounds and taxanes and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation. | 2015-10-22 |
20150297622 | PRODUCT AND METHOD FOR SUPPORTING URIDINE HOMEOSTASIS - This invention pertains to the use of an uridine source, preferably uridine monophosphate, for increasing, controlling and/or maintaining fasting plasma uridine concentrations in a range of 4 to 8 μM in a subject in need thereof, comprising administering to said subject a composition comprising 300-900 mg of said uridine source daily for a period of at least 4 weeks. In particular, the use of an uridine source is intended forelderly and/or subjects suffering from neurological disorders such as Alzheimer's Disease and dementia syndromes. | 2015-10-22 |
20150297623 | METHODS FOR TREATMENT OF PRIMARY CANCER AND CANCER METASTASIS - Embodiments of the invention are directed to administering a therapeutically effective amount of a purinergic P2 receptor agonist alone or in combination with adenosine receptor antagonist and/or other anti-cancer therapies for the treatment of cancer. Agonist for the P2 receptors include non-hydrolysable ATP analogs. In particular aspects the cancer is a metastatic cancer, such as a bone metastasis. | 2015-10-22 |
20150297624 | DEFIBROTIDE FOR USE IN PROPHYLAXIS AND/OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD) - Defibrotide for use in prophylaxis and/or treatment of Graft versus Host Disease (GVHD) in humans is disclosed, preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. Graft versus Host Disease of the invention (GVHD) can be acute aGVHD and/or chronic cGVHD, preferably acute. | 2015-10-22 |
20150297625 | In Vivo Delivery of Nucleic Acids to the Liver or Liver Tissue - The invention encompasses methods of delivering nucleic acids, including dsRNA, to mammalian target cells in vivo via intercellular transfer, wherein the dsRNA is delivered to or expressed in a first cell different from the target cell, wherein the first cell facilitates delivery of the dsRNA to the target cell. | 2015-10-22 |
20150297626 | Combination for use in treating diseases or conditions associated with melanoma, or treating diseases or conditions associated with activated B-raf pathway - The invention relates to the therapeutic use of a combination in a disease and condition associated with melanoma or a disease or a condition associated with activated BRAF pathway. | 2015-10-22 |
20150297627 | Methods and Compositions for treatment of cancer by inhibition of NR2F2 - The current invention discloses compositions of matter, protocols and methods of use of treatment for cancer and other diseases of aberrant cellular proliferation and differentiation by inhibiting expression of NR2F2 or activity thereof. In one embodiment, administration of synthetic oligonucleotides that induce RNA interference mediated degradation of the nuclear receptor NR2F2 in human or animal patients is performed at a sufficient concentration or frequency to achieve regression of tumor. | 2015-10-22 |
20150297628 | METHODS FOR THE TREATMENT AND DIAGNOSIS OF ATHEROSCLEROSIS - The present invention relates to the treatment and the diagnosis of atherosclerosis, in particular to a miRNA for use in the treatment and the diagnosis of atherosclerosis. | 2015-10-22 |
20150297629 | MODULATION OF RENIN-ANGIOTENSIN SYSTEM (RAS) RELATED DISEASES BY ANGIOTENSINOGEN - Disclosed herein are antisense compounds and methods for modulating AGT and modulating a RAS pathway related disease, disorder or condition in an individual in need thereof. RAS related diseases in an individual such as hypertension or organ damage can be treated, ameliorated or prevented with the administration of antisense compounds targeted to AGT. | 2015-10-22 |
20150297630 | METHODS AND COMPOSITIONS FOR ADMINISTRATION OF IRON - The present invention generally relates to treatment of iron-related conditions with iron carbohydrate complexes. One aspect of the invention is a method of treatment of iron-related conditions with a single unit dosage of at least about 0.6 grams of elemental iron via an iron carbohydrate complex. The method generally employs iron carbohydrate complexes with nearly neutral pH, physiological osmolarity, and stable and non-immunogenic carbohydrate components so as to rapidly administer high single unit doses of iron intravenously to patients in need thereof. | 2015-10-22 |
20150297631 | TUSC2 THERAPIES - A method for predicting a subject's response to a TUSC2 therapy is provided. In particular, a subject's response is predicted based on the proportion of cancers cells that are apoptotic. Also provided is a method of treating a subject previously predicted to have a favorable response with a TUSC2 therapy. Methods for treating cancer by administration of a TUSC2 therapeutic in conjunction with an EGFR inhibitor and/or a protein kinase inhibitor are also disclosed. Kits and reagents for use in TUSC2 therapy are provided. | 2015-10-22 |
20150297632 | CHITIN OR DERIVATIVES THEREOF FOR THE PREVENTION AND/OR TREATMENT OF PARASITOSES - The subject matter of the present invention is the use of chitin or a derivative of chitin for preventing and/or treating parasitoses, and in particular cryptosporidiosis. The present invention also pertains to a composition that comprises at least one base agent chosen from among chitin or a derivative of chitin and at least one secondary agent chosen from among an agent for stimulating immunity and an antiparasite agent, as well as the use of same for preventing and/or treating parasitoses, in particular cryptosporidiosis. | 2015-10-22 |
20150297633 | TREATMENT OF BONE MARROW EDEMA (OEDEMA) WITH POLYSULFATED POLYSACCHARIDES - A method for the treatment of bone marrow edema in a mammal comprising administering an effective amount of a polysulfated polysaccharide including salts thereof, to a mammal in need of such treatment. | 2015-10-22 |
20150297634 | Materials and Methods for Preventing and Treating Anastomotic Leaks - Materials and methods for preventing and treating anastomotic leaks are disclosed. Data establishes that pathogenic microbes interfere with establishing epithelial cell barriers in anastomoses and, more generally, with the reconnection of any two portions of like or different tissues comprising epithelia. Suitable prophylactic and therapeutic composition comprise, e.g., a phosphorylated high molecular weight polyethylene glycol compound. | 2015-10-22 |
20150297635 | METHOD FOR TREATING ACUTE KIDNEY INJURY - The present invention provides methods for treating acute kidney injury through introduction of one or more drag reducing polymers, oligomers, and/or monomers, as well as compositions that include therapeutic amounts of one or more of these drag reducing polymers, oligomers, and/or monomers. These compositions may also include additional components that enhance at least one of the stability, effectiveness, or administerability of the polymers, oligomers, and/or monomers—such as buffers, anti-oxidants, and enzyme inhibitors. | 2015-10-22 |
20150297636 | MATERIALS AND METHODS FOR TREATING DIARRHEA - The present invention provides therapeutic compositions and methods for treating gastrointestinal diseases and conditions such as diarrhea, for providing rehydration, for correcting electrolyte and fluid imbalances, and/or for improving small intestine function. In one embodiment, the present invention provides a composition formulated for enteral administration, wherein the composition does not contain glucose. In a preferred embodiment, the composition is formulated for administration as an oral rehydration drink. | 2015-10-22 |
20150297637 | ACTIVATED CARBON COMPRISING AN ADSORBED IODIDE SALT IN A METHOD FOR TREATING CHRONIC BRONCHITIS - The present invention provides activated carbon comprising an adsorbed iodide salt selected from the group of alkali metal iodides and earth alkali iodides, for use in a method for treating chronic bronchitis. | 2015-10-22 |
20150297638 | CHEMICALLY INDUCED PLURIPOTENT STEM CELLS FOR SAFE THERAPEUTIC APPLICATIONS - This disclosure provides a chemically modified induced pluripotent stem (iPS) cells characterized by DNA hypomethylation and methods for generating the cells. The cells are useful in method for or regenerating cardiac muscle tissue or to promote the replacement of cardiac scar tissue in a patient in need thereof and to treat cardiac disease. | 2015-10-22 |
20150297639 | TREATING CANCER - The specification provides compositions and methods for treating cancer with non cancerous cell extracellular vesicles. Extracellular vesicles act as a surrogate microenvironment to reverse the drug-resistance or cancerous phenotype of cancer cells towards a non cancerous phenotype. | 2015-10-22 |
20150297640 | Method of Controlling Administration of Cancer Antigen - The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific T cells that express a viral antigen T cell receptor and a cancer antigen-specific chimeric receptors and triggering their activation by also administering antigen-presenting T-cells which express viral antigen. These bi-specific T cell clones are a source of effector cells that persist in vivo in response to stimulation with viral antigen, leading to long-term function after their transfer to patients with cancer and autoimmune diseases. | 2015-10-22 |
20150297641 | ALLERGY TREATMENT USING ACID TREATED AQUEOUS WHEY PROTEIN EXTRACT - The invention relates to manufacture of whey protein extracts, to infant formula and to reducing or preventing food allergy. The whey protein extract is produced from a whey protein-containing composition by contacting a whey protein-containing composition with an aqueous solution to form a sample including a soluble protein-containing component and an insoluble component; recovering the soluble protein-containing component from the sample; and acidifying the soluble protein-containing component, thereby producing the whey protein extract. Extracts produced by the method of the invention may be used in infant formula, as a dietary supplement or foodstuff. | 2015-10-22 |
20150297642 | COMPOSITIONS FOR THE RESTORATION OF A FECAL MICROBIOTA AND METHODS FOR MAKING AND USING THEM - In alternative embodiments, the invention provides compositions and methods for treating various disorders and conditions in mammals, including chronic disorders in which there is a presence of an abnormal microbiota or an abnormal distribution of microflora in the gastrointestinal tract. In alternative embodiments, the invention provides liquid preparations or formulations derived from a human fecal material (e.g., a stool) processed, e.g., filtered and/or centrifuged, such that all bacteria, fungal spores and viruses are removed, but retaining the native biologically active molecules from the fecal material and bacteriophages. In alternative embodiments, the invention provides a “rough-”, “incomplete-” or medium-filtered microbiota which still comprises native physiological components or nutritive agents for the bacteria, e.g., retains native biologically and nutritionally active components. In alternative embodiments, the invention provides a highly filtered or substantially purified microbiota in combination with, or having added back, a liquid preparation or formulation of the invention. In alternative embodiments, the invention provides compositions or formulations where the bacteria, or microbiota, component has been cultured, or cultured under anaerobic conditions, or harvested, stored and/or cultured under anaerobic conditions. In alternative embodiments, the invention provides various additives, compositions and donor restrictions for treating these disorders and conditions. | 2015-10-22 |
20150297643 | INHIBITION OF RHO AND OR ROCK AND CELL TRANSPLANTATION - The present disclosure provides a multi-treatment combination to improve recovery after spinal cord injury or neurotrauma comprising: (a) Cell transplantation at the site of spinal cord injury and (b) Surgical delivery of BA-210. The combined treatment allows cells to be transplanted in the injury site during the acute trauma period, a time when the inflammatory response to neurotrauma adversely effects survival of transplanted cells. Early therapy delivered during critical care treatment after neurotrauma is essential for successful restorative therapy. The multi-treatment combination also provides a method to ensure that multi-potent transplanted cells do not become tumorigenic. | 2015-10-22 |
20150297644 | CO-PROCESSING METHODS FOR HONEY NASAL RINSE PRODUCTION - Nasal rinse compositions are disclosed. The nasal rinse comprises a dried particulate composed of honey and a carrier. The composition may be a co-processed composition wherein the honey and carrier are combined while the honey is in liquid form and processed together to produce the dried particulate. Methods for producing the nasal rinse compositions are also provided, as well as methods of use of the nasal rinse compositions for the prevention or treatment of nasal infection, rhinitis, or sinusitis. | 2015-10-22 |
20150297645 | CYCLIC DI-AMP INDUCTION OF TYPE I INTERFERON - Methods of modulating type-I interferon production in a cell are provided. | 2015-10-22 |
20150297646 | Use of a Lactobacillus rhamnosus strain for reducing weight gain and/or insulin resistance - Provided are the use of | 2015-10-22 |
20150297647 | ENTEROCOCCUS FAECIUM EF08 STRAIN, A USE, A FEED ADDITIVE AND A FEED THEREOF | 2015-10-22 |
20150297648 | PREBIOTIC COMPOSITIONS COMPRISING ONE OR MORE TYPES OF BACTERIOPHAGE - Disclosed herein are compositions that comprise one or more types of bacteriophage and methods of using such bacteriophages as a prebiotic to promote the growth of beneficial bacteria by decreasing harmful bacterial populations and releasing nutrients into the environment for good bacteria in the digestive system of an individual. | 2015-10-22 |
20150297649 | TRPV1 MODULATORY GENE PRODUCT THAT AFFECTS TRPV1-SPECIFIC PAIN BEHAVIORAL RESPONSES IDENTIFIED IN A FUNCTIONAL SCREEN OF AN HSV-BASED cDNA LIBRARY - The invention provides a method for ameliorating chronic pain signaling involving transient receptor potential cation channel subfamily V member | 2015-10-22 |
20150297650 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition contains a coxsackievirus A11 type that infects cancer cells or an echovirus 4 type that infects cancer cells. The coxsackievirus A11 type and the echovirus 4 type may have capsid eliminated. The pharmaceutical composition has an intensive cytotoxicity to a cell of cancer selected from the group consisting of small cell lung cancer, non-small cell lung cancer, lung squamous cell carcinoma, malignant mesothelioma, colorectal cancer, colon/rectum caner, esophageal cancer, hypopharynx cancer, human-B-lymphocyte tumor, breast cancer, cervical cancer, and pancreatic cancer, which is the cancer cells of a solid cancer. | 2015-10-22 |
20150297651 | LIVING BODY HEALING ACCELERATOR - The present invention provides a living body healing, having an accelerating activity in the regeneration ability relating to the cure of damages of cells or tissues caused by toxicity of a drug or a wound in a living body, having high safety, and also not causing any side effect even administered for a long period of time. Problems are solved by a living body healing accelerator containing as an active constituent a mixture of a culture solution obtained after cultivation of a microorganism belonging to the | 2015-10-22 |
20150297652 | COMPOSITIONS AND METHODS FOR THEIR DERMATOLOGICAL USE - Compositions containing | 2015-10-22 |
20150297653 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING - The present invention provides for methods of obtaining an extract of | 2015-10-22 |
20150297654 | PHARMACEUTICAL COMPOSITION AND METHOD OF MANUFACTURING - The present invention provides for methods of obtaining an extract of | 2015-10-22 |
20150297655 | Rhus Coriaria L. Extract For Use In The Treatment Of Hyperhidrosis - Extracts of | 2015-10-22 |
20150297656 | Atractylodes Lancea extract feed additive and preparation method thereof | 2015-10-22 |
20150297657 | Portulaca oleracea L. extract feed additive and preparation method thereof | 2015-10-22 |
20150297658 | TREATMENT OF NEUROCUTANEOUS SYNDROME, INCLUDING COMPOSITIONS, METHODS AND USES THEREOF - A treatment protocol for use in the treatment of neurocutaneous syndrome is described and comprises at least one xanthone component, which may comprise at least one mangosteen component, and/or at least one detoxification component. Additional embodiments comprise at least one herbal component, at least one vitamin component, or a combination thereof. A method of treating a patient having neurocutaneous syndrome is described herein and comprises: providing at least one xanthone component, which may comprise at least one mangosteen component, providing at least one xanthone component, which may comprise at least one mangosteen component, to the patient, and administering the at least one detoxification component to the patient. Additional methods steps may include providing and administering at least one herbal component, providing and administering at least one vitamin component or a combination thereof. | 2015-10-22 |
20150297659 | BEAUTYBERRY TOTAL GLYCOSIDES EXTRACT AND PREPARATION METHOD AND USE THEREOF - Disclosed is a composition comprising an beautyberry total glycosides extract, and a method of preparation thereof, and the use of the composition thereof in preparing drugs for treating neurodegenerative diseases or skin diseases. The extract thereof is prepared from the leaves of | 2015-10-22 |
20150297660 | Magnolia officinalis Rehd. et Wils. extract feed additive and preparation method thereof | 2015-10-22 |
20150297661 | ANALGESIC COMPOSITIONS AND METHODS OF USE - The invention relates to the fields of pharmacology and medicine, and provides anesthetic compositions and methods for the treatment of pain using compositions comprising Tea tree oil and one or more additional agent. The invention relates to analgesic compositions for the treatment of pain associated with a variety of disorders or conditions, particularly oral or dental disorders or conditions such as alveolar osteitis or dental caries. | 2015-10-22 |
20150297662 | RAPAMYCIN 40-O-CYCLIC HYDROCARBON ESTERS, COMPOSITIONS AND METHODS - A new class of rapamycin 40-O-cyclic hydrocarbon esters is disclosed. The 40-O position of the rapamycin ester has the form 40-O—R, where R is C(O)—(CH | 2015-10-22 |
20150297663 | Zoe's Divine Cream - The invention reveals a “Health, Wellness And Maintenance Product”, as well as the formula and mixture process for its preparation. The art of this invention is a “Health and Wellness Product”. Disclosing a Massage Cream found to contain many benefits to the human condition. Users boast of numerous benefits upon repeated use. The art of the invention positively benefits users, according to feedback received. It has been found beneficially soothing to the body. All benefits for this art have not been disclosed, and/or discovered, at this time. The invention promotes a “Healthier Body”. It's composition comprising Natural Herbal Product Components and Homeopathic Product Components. All of which are previously approved for human consumption, and or use. | 2015-10-22 |
20150297664 | COMPOSITION FOR PREVENTING ALZHEIMER'S DISEASE, CONTAINING PURPLE BAMBOO SALT, AND METHOD FOR PREPARING PURPLE BAMBOO SALT - Provided is a functional composition for preventing an Alzheimer's disease, in which the composition includes heat-treated salt that is heat-treated at 800° C. to 1200° C. as an effective component and other pharmaceutically or sitologically acceptable components. The composition can prevent an Alzheimer's disease by effectively blocking the cause path of an Alzheimer's disease in a human body. | 2015-10-22 |
20150297665 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING LAMINITIS, FOUNDER AND OVEREATING IN AN UNGULATE - The present invention relates to the production and use of feed compositions useful in the treatment and prevention of laminitis, founder and overeating, particularly in horses and ponies. The feed composition may reduce the effects of carbohydrate overload whilst providing a controlled release of metabolizable energy to avoid excessive fermentation and lactic acid production in the hind gut. At the same time the feed composition can provide nutrition to the animal whilst avoiding overeating. The combination of controlled bulk and energy provides for a feed composition that can control the symptoms of excess energy sources in the gut which may manifest as laminitis and founder. | 2015-10-22 |
20150297666 | COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND MYOCARDIAL INFARCTION WITH DIPEPTIDYL PEPTIDASE INHIBITORS OR B TYPE NATRIURETIC PEPTIDE ANALOGUES RESISTANT TO PROLYL-SPECIFIC DIPEPTIDYL DEGRADATION - The present invention describes compositions and methods for treating cardiovascular disease and myocardial infarction using dipeptidyl peptidase inhibitors. Also provided are methods for increasing natriuretic peptide function by administering one or more analogues of B type natriuretic peptide that provide increased stability in the presence of prolyl-specific dipeptidyl peptidases. | 2015-10-22 |
20150297667 | PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS OF USE COMPRISING SELECTIVE AGONISTS OF MELANOCORTIN 1 RECEPTOR - Short tri- and tetrapeptides according to the following Formula I Ar(CH2) | 2015-10-22 |
20150297668 | ANALOGS OF C5a AND METHODS OF USING SAME - Materials and methods for treating and preventing an infection or disease, and for directly killing microorganisms, using carboxy-terminal C5a analogs, are provided. | 2015-10-22 |
20150297669 | PHARMACEUTICAL COMPOSITION FOR TREATING MEDICAL CONDITIONS AND A METHOD FOR TREATING ALIMENTARY DISORDERS AND RELATED DISEASES - The present invention refers to a pharmaceutical composition that comprises an active ingredient, such as a peptide, which acts as an antagonist and/or inverse agonist of a G protein-coupled receptor and pharmaceutically acceptable vehicle. Said pharmaceutical composition may be used for the treatment of obesity and the prevention of and the treatment of diabetes. | 2015-10-22 |
20150297670 | "Therapeutic Use of Peptide Inhibitors of NADPH Oxidase; Aerosolization as a Delivery Mechanism" - A method is provided for treatment of a condition mediated by Nox2 in a patient. The method comprises administering to the patient by inhalation a polypeptide as described herein, able to inhibit superoxide production by Nox2. Conditions treatable in this manner include, without limitation, one or more of: right ventricular hypertrophy; pulmonary hypertension; acute lung injury; obstructive sleep apnea; ischemia/reperfusion injury in the lung; pulmonary fibrosis; an obstructive lung disorder such as Chronic Obstructive Pulmonary Disease (COPD), asthma, cystic fibrosis and emphysema; and atherosclerosis | 2015-10-22 |
20150297671 | PEPTIDE ANALOGUES WITH BRANCHED AMINO ACID PROBE(S) - The present invention relates to peptide analogues comprising one or more branched amino acid probes and a peptide, native or variants thereof. | 2015-10-22 |
20150297672 | Alpha- and gamma-MSH analogues - The present invention provides peptide analogues of α-MSH and γ-MSH, comprising the amino acid sequence of human α-MSH or γ-MSH, or variants thereof, and having a branched amino acid probe in the N-terminal part of the peptide. | 2015-10-22 |
20150297673 | NOVEL ANTI-BIOTIC PEPTIDE ORIGINATED FROM RIBOSOMAL PROTEIN L1 OF HELICOBACTER PYLORI AND USE OF THE SAME - The present invention relates to a novel antibiotic peptide originated from the ribosomal protein L1 of | 2015-10-22 |
20150297674 | SUBSTANCES AND METHODS FOR THE TREATMENT OF CEREBRAL AMYLOID ANGIOPATHY RELATED CONDITIONS OR DISEASE - A substance for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system; and a vehicle for transporting the inhibitor into the cerebrovasculature; where the inhibition by the inhibitor is sufficient to decrease the incidence of or to prevent the incidence of cytolysis of the smooth muscle cells. A method for treating a cerebral amyloid angiopathy related condition or disease affecting cerebrovasculature in a patient, comprising: a) identifying a patient with a cerebral amyloid angiopathy related condition or disease; b) providing one or more than one substance that comprises an inhibitor that causes inhibition of the formation of membrane attack complex of the complement system, c) administering one or more than one dose of the one or more than one substance to the patient. | 2015-10-22 |
20150297675 | USE OF A VEGF ANTAGONIST IN TREATING OCULAR VASCULAR PROLIFERATIVE DISEASES - The present invention relates to the use of a non-antibody VEGF antagonist, in the treatment of choroidal neovascularisation secondary to diseases other than age-related macular degeneration and pathologic myopia. | 2015-10-22 |
20150297676 | COMPOSITION COMPRISING GRIM-19 AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING OBESITY OR LIPID-RELATED METABOLIC DISEASES - The present invention relates to a composition comprising GRIM-19 protein as an active ingredient for preventing or treating obesity or lipid-related metabolic diseases. More particularly, the present invention relates to a composition for preventing or treating obesity or lipid-related metabolic diseases wherein the composition comprises GRIM-19 protein as an active ingredient for preventing or treating metabolic diseases caused by immune response disorders or interactions between genetic, metabolic, or environmental complex factors. The GRIM-19 protein according to the present invention exhibits excellent effectiveness not only in reducing lipocytes and total cholesterol content in the body, but also in suppressing the differentiation of cytotoxic Th17 cells that produce and secrete inflammatory cytokines. Also, GRIM-19 has been found to have excellent effectiveness in regulating a STAT3 mediated inflammatory response in an inflammatory environment related to obesity. Thus, the present invention can be used for preparing a treatment agent and a functional food that can effectively treat obesity or lipid-related metabolic diseases. | 2015-10-22 |
20150297677 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ENTRY - The invention provides methods, compositions, and kits featuring agents that inhibit viral entry mediated by T-cell Immunoglobulin and Mucin-domain containing proteins (TIM proteins) and other phosphatidylserine receptors. | 2015-10-22 |
20150297678 | COMPOSITIONS AND METHODS OF ENHANCING WEIGHT GAIN - The present invention generally relates to compositions and methods of enhancing weight gain and/or myogenesis in a subject (e.g., a subject afflicted with cachexia) by the administration of fibroblast growth factor. | 2015-10-22 |
20150297679 | METHODS AND ASSAYS RELATING TO MACROPHAGE DIFFERENTIATION - The technology described herein is directed to methods and assay related to macrophage differentiation and the role of such in pathogenesis. | 2015-10-22 |
20150297680 | COMPOSITIONS AND METHODS FOR INCREASING PROTEIN HALF-LIFE - In order to extend the serum half-life of a protein, we exploited the site-specific fatty acid-conjugation to a permissive site of a protein, using copper-catalyzed alkyne-azide cycloaddition, by linking a fatty acid derivative to p-ethynylphenylalanine incorporated into a protein using an engineered pair of yeast tRNA/aminoacyl tRNA synthetase. As a proof-of-concept, we show that single palmitic acid conjugated to superfolder green fluorescent protein (sfGFP) in a site-specific manner enhanced a protein's albumin-binding in vitro about 20 times and the serum half-life in vivo 5 times when compared to those of the unmodified sfGFP. Furthermore, the fatty acid conjugation did not cause a significant reduction in the fluorescence of sfGFP. Therefore, these results clearly indicate that the site-specific fatty acid-conjugation is a very promising strategy to prolong protein serum half-life in vivo without compromising its folded structure and activity. | 2015-10-22 |
20150297681 | Pegylated Insulin Lispro Compounds - The present invention relates to the field of diabetes. More particularly, the invention relates to PEGylated insulin lispro compounds that are PEGylated with high molecular weight poly(ethylene glycol), are highly soluble at physiological pH, have an extended duration of action, and characterized by pharmacokinetic, pharmacodynamic, and/or activity peak-trough ratios of less than 2. The invention also relates to methods of providing such molecules, to pharmaceutical compositions containing them, and to their therapeutic uses. | 2015-10-22 |
20150297682 | METHOD OF TREATING CANCER USING HIGH EFFICIENCY SELF-ILLUMINATIVE NANOCOMPLEXES AND METHOD OF MANUFACTURING THE SAME - The present disclosure relates to a method of treating cancer using a composition including a target-specific self-illuminative nanocomplex which includes an self-illuminative nanocomplex including a quantum dot and a modified self-illuminative protein (m-Rluc8), a targeted cancer-specific molecule and a hydrophilic polymer, and a method of preparing the composition. | 2015-10-22 |
20150297683 | METHOD TO INCREASE THE ABSORPTION OF UNSATURATED FATTY ACIDS BY HUMAN INFANTS - The present invention relates to a method to increase the absorption by a human infant of at least one unsaturated fatty acid, said method comprising the enteral administration to said infant of recombinant human bile-salt-stimulated lipase (rhBSSL). In another aspect the invention also relates to a method to improve the visual and/or cognitive development of a human infant, said method comprising the enteral administration to said infant of rhBSSL. Such methods have particular utility for preterm human infants, particular those in medical need of increasing their absorption of or availability to such unsaturated fatty acids. In further aspects, the invention relates to kits, packaged-pharmaceutical-products, recombinant human bile-salt-stimulated lipase and pharmaceutical compositions, in each case useful for increasing the absorption by a human infant of at least one unsaturated fatty acid, or for increasing the visual and/or cognitive development of a human infant. | 2015-10-22 |
20150297684 | Extended Length Botulinum Toxin Formulation for Human or Mammalian Use - An extended duration pharmaceutical composition including a botulinum neurotoxin, an adhesive agent, and a stabilizing macromolecule is disclosed. The composition effectively has all the properties to cause chemodenervation through a facial muscle, or other muscle, that predecessor botulinum toxin preparations have had as well as agents which create a fibrotic adhesion on the under surface of facial muscles (or other muscles) to the facial bone (or other bones) so that the facial bone tethers the under surface of the facial muscle, thereby causing fibrosis to the underlying fat pad. The composition can be used to treat various disorders. Methods of modifying facial contour for functional or cosmetic purposes in a human patient are disclosed which involve injecting a therapeutically effective amount of the disclosed compositions. A method of quantifying the extended duration of the compositions is also disclosed. | 2015-10-22 |
20150297685 | FIBRINOLYTIC COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF PHLEBOTHROMBOTIC STATES - Disclosed are compositions comprising bromelain and nattokinase, including as the only active ingredients. The composition may be administered orally, and may be in the form of bi-layer tablets. Methods of treating thrombophlebitis are also disclosed. | 2015-10-22 |
20150297686 | TISSUE REGENERATION PROMOTING AGENT - The purpose of the present invention is to provide a novel tissue regeneration accelerator and tissue regeneration method. The present invention relates to: a composition for accelerating tissue regeneration, accelerating cell differentiation and/or accelerating cell multiplication comprising a component selected from the group consisting of activated stellate cells, the decomposition product of activated stellate cells, MMP14, collagen that has been treated with MMP14, and the secretion product of activated stellate cells; a composition for suppressing cell multiplication comprising MMP14 suppressing material; and a cell cultivation substrate comprising collagen that has been treated with MMP14. | 2015-10-22 |
20150297687 | PROTEASE COMPOSITIONS FOR THE TREATMENT OF DAMAGED TISSUE - The invention is directed to compositions containing one or more proteases that are beneficial in the treatment of damaged tissue, wounds and inflammation. The compositions of the invention modulate the levels and activity of proteins that are present at wound and inflammation sites and promote the repair of damaged tissue. | 2015-10-22 |
20150297688 | Botulinum Toxin and the Treatment of Primary Disorders of Mood and Affect - A method of treating depression includes identifying a subject with a pain syndrome for increased responsiveness to the treatment of pain associated with the pain syndrome with botulinum toxin and locally administering a botulinum toxin subcutaneously to a face of the subject, thereby treating said pain. Identification of the pain is made prior to administering botulinum toxin for the treatment of said pain. The subject has a pain syndrome and a condition selected from the group consisting of a depressive disorder, an anxiety disorder and a sleep disorder. | 2015-10-22 |
20150297689 | BETA-LACTAMASES WITH IMPROVED PROPERTIES FOR THERAPY - This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as | 2015-10-22 |
20150297690 | NOVEL PROTEIN MATERIAL - The invention relates to a protein material includes angiogenin and/or angiogenin hydrolysate in an amount of 2 to 15 mg/100 mg, and lactoperoxidase and/or lactoperoxidase hydrolysate, in the mass ratio to angiogenin and/or angiogenin hydrolysate of 0.3 to 20. | 2015-10-22 |
20150297691 | USE OF ANTAGONISTS OF GHRELIN OR GHRELIN RECEPTOR TO PREVENT OR TREAT STRESS-SENSITIVE PSYCHIATRIC ILLNESS - The invention relates to methods of protecting against chronic stress in a subject and treating stress sensitive disorders in a subject by antagonizing ghrelin or ghrelin receptor. | 2015-10-22 |
20150297692 | Composition Comprising the Amyloid Beta 1-6 Peptide Coupled to a Virus-Like Particle and an Adjuvant - The present invention relates to compositions comprising a construct comprising the Aβ1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type. | 2015-10-22 |
20150297693 | PEPTIDE INHIBITORS FOR MEDIATING STRESS RESPONSES - The present invention relates to peptides capable of inhibiting cellular and immune stress responses in a eukaryotic cell. The invention provides compositions and methods for the treatment of human degenerative diseases and inflammation, utilizing these peptides. | 2015-10-22 |
20150297694 | CANCER DIAGNOSTIC AND THERAPEUTIC METHOD TARGETING MOLECULES EXPRESSED IN CANCER STEM CELLS - The present invention provides a novel method for determining cancer malignancy, a novel cancer diagnostic method, a novel method for determining prognosis, a novel vaccine for cancer treatment, and a novel vaccine for suppressing cancer metastasis. Specifically, the invention provides a cancer malignancy evaluation method that comprises the step of measuring a DDX3X expression level in a cancer tissue, and the step of evaluating malignancy of the cancer tissue by using the DDX3X expression level. | 2015-10-22 |
20150297695 | XBP1, CD138, AND CS1 PEPTIDES, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THE PEPTIDES, AND METHODS OF USING SUCH PEPTIDES AND COMPOSITIONS - The disclosure features, inter alia, immunogenic XBP1-, CD138-, and CS1-derived peptides (and pharmaceutical compositions thereof). The peptides can be used in a variety of methods such as methods for inducing an immune response, methods for producing an antibody, and methods for treating a cancer (e.g., breast cancer, colon cancer, pancreatic cancer, a blood cancer, e.g., leukemia or a plasma cell disorder such as multiple myeloma or Waldenstrom's macroglobulinemia). The peptides (and pharmaceutical compositions comprising the peptides) can be used, e.g., in a method of treating a precancerous condition such as smoldering multiple myeloma. The peptides can also be included in MHC molecule multimer compositions and used in, e.g., methods for detecting a T cell in a population of cells. | 2015-10-22 |
20150297696 | COMPOSITIONS OF A CARBOHYDRATE VACCINE FOR INDUCING IMMUNE RESPONSES AND USES THEREOF IN CANCER TREATMENT - The invention encompasses therapeutic compositions including Globo H-KLH conjugates and/or therapeutic antibodies as well as methods of making and using the same to treat proliferative diseases such as cancer. The therapeutic conjugates include an antigen linked to a carrier. In particular the therapeutic conjugates include a Globo H moiety and a KLH moiety and/or a derivatized KLH moiety subunit optionally linked via a linker. The therapeutic compositions are in part envisaged to act as cancer vaccines for boosting the body's natural ability to protect itself, through the immune system from dangers posed by damaged or abnormal cells such as cancer cells. An effective immune response is one that reduces the severity of disease, including but not limited to, prevention of disease, delay in onset of disease, decreased severity of symptoms, decreased morbidity and delayed mortality. | 2015-10-22 |
20150297697 | CANCER-ASSOCIATED ANTIGEN RELATED APPLICATIONS - The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits. | 2015-10-22 |
20150297698 | THERAPEUTIC CANCER VACCINES DERIVED FROM A NOVEL DENDRITIC CELL LINE - The invention is in the field of medical sciences. It provides means and methods for the treatment of cancer. More in particular, it provides cells and cell lines that can be developed into fully functional dendritic cells. These cells endogenously express cancer-specific antigens, which makes them particularly suited for the treatment of different kinds of cancer. More in particular, the invention relates to a precursor cell line for dendritic cells called DC-One as deposited at the DSMZ under accession number DSMZ ACC3189 on Nov. 15, 2012. | 2015-10-22 |